Description

Bausch Health Companies’ Solta Revenue Jumps 38% as China Growth Explodes; But Can It Sustain?

Bausch Health reported robust second-quarter results in 2026, marking its 13th consecutive quarter of both top-line and bottom-line growth, supported by solid performance across all business segments. Consolidated revenue increased by 13% (11% organic) to $2.85 billion, while adjusted EBITDA rose 28% to $1.08 billion, representing a 59% adjusted EBITDA margin—a 530 basis point improvement year-over-year. Adjusted cash flow from operations also grew significantly by 44% to $637 million. The company’s strong operational execution facilitated a $434 million reduction in net debt to $13.7 billion, continuing a downward trend since debt refinancing in 2022. Excluding the Bausch + Lomb segment, which had a 9% revenue increase, Bausch Health’s core business saw revenues of $1.46 billion, up 16%, and adjusted EBITDA of $865 million, up 28%.